Patients’ and Healthcare Professionals’ Experiences of Idiopathic Pulmonary Fibrosis Treatment with the Pirfenidone 801 mg Tablet Formulation: A Multinational Survey

Patients’ and Healthcare Professionals’ Experiences of Idiopathic Pulmonary Fibrosis Treatment with the Pirfenidone 801 mg Tablet Formulation: A Multinational Survey

Abstract Introduction Idiopathic pulmonary fibrosis (IPF) is a progressive, debilitating interstitial lung disease. Two antifibrotics, pirfenidone and nintedanib, are available for IPF treatment. Pirfenidone is available as 267 mg capsules and, more recently, as 267 mg and 801 mg tablets. The aim of...

Full description

Bibliographic Details
Main Authors: Lisa H. Lancaster, Claudia Valenzuela, Wendi Mason, Claus Neurohr, Elena Ripamonti, Klaus-Uwe Kirchgaessler, Vincent Cottin
Format: Article
Language:English
Published: Adis, Springer Healthcare 2020-03-01
Series:Pulmonary Therapy
Subjects:
Antifibrotics
Idiopathic pulmonary fibrosis
Pill burden
Pirfenidone
Quality of life
Questionnaire
Online Access:https://doi.org/10.1007/s41030-020-00111-y

Internet

https://doi.org/10.1007/s41030-020-00111-y

Similar Items